Matt Byerly, MD

Director, Center for Mental Health Research and Recovery, Montana State University
Professor, Department of Cell Biology and Neuroscience, Montana State University

Dr. Matt ByerlyResearch Interests
Dr. Byerly, a psychiatrist with expertise in clinical and translational mental health research, joined Montana State University as the Director of the new Center for Mental Health Research and Recovery in August of 2015. In the preceding 18 years, he was the Director of the Schizophrenia and Adult Fragile X Research Programs at UT Southwestern Medical Center.  He is a leader in research related to medication adherence, having developed the internationally-recognized Brief Adherence Rating Scale (BARS).  He is currently the principal investigator of a large, multi-site study that is evaluating the clinical utility of the BARS.  Dr. Byerly has served on multiple Scientific Advisory Boards including the Food and Drug Administration Psychopharmacologic Drugs Advisory Committee. He has also been a committed educator, mentoring many clinicians and early psychiatric researchers and serving as an Associate Psychiatric Training Director for Research and Didactic Learning.  His research efforts now involve collaborations on issues of high mental health relevance for Montana, including suicide prevention, addressing mental health needs of rural and frontier settings, the mental health needs of Native Americans and military veterans, and pursuing improved methods to diagnosis and treatment mental disorders.

Website
http://www.montana.edu/cmhrr/

Janet Lindow, PhD

Assistant Professor, Center for Mental Health Research and Recovery, Montana State University

Dr. Janet LindowResearch Interests
Dr. Lindow has over 20 years of research experience on topics ranging from clinical trial management to basic research in microbiology, translational immunology, vaccine development, and biochemistry. Specifically, she has developed translational research programs for dengue viruses, typhoid fever, campylobacteriosis, and leptospirosis diseases, and assisted with the design and performance of early phase vaccine clinical trials and diagnostic test development. While junior faculty at the Yale School of Public Health, she spent several years working in the urban slums of Salvador, Brazil where she and her team discovered a novel, potential therapeutic for patients with severe leptospirosis. She joined CMHRR in 2016 to apply her expertise in translational and clinical research to combat mental health diseases.

Website
http://www.montana.edu/cmhrr/